ERIS Lifesciences Ltd

- No explicit mention of new fundraising through debt or equity in the provided excerpts. - Management emphasized "heads down execution" with no acquisitions unless the balance sheet improves, implying caution on new debt or equity raises. - Debt reduction is a priority, aiming to reduce Net Debt to Rs. 2,600 crores by FY25 end and around Rs. 2,000 crores by FY26. - Operating cash flow expected to fund capex and debt servicing, suggesting no immediate need for external fundraising. - Capex for biotech expansion and site acquisition is planned within existing financial guidance (Rs. 200 crores over FY25-26 for insulin, MAB, hormones). - Focus remains on rebuilding balance sheet strength rather than raising new funds at this time.

- Insulin manufacturing plant investment: Additional capex of Rs. 20-25 crores planned for the insulin piece at the acquired plant, included within the identified capex and not incremental. (Page 20) - Biotech segment capex: Rs. 100-120 crores additional capex envisaged for various Biotech segments including Insulin, MABs, and Hormones, with Rs. 200 crores planned over FY25 and FY26 for Insulin, MABs, and Hormone manufacturing combined. (Pages 8, 19) - Manufacturing lines: Plan to install six lines for Insulin (four for vials, two for cartridges), two lines for MABs, and additional hormone lines in early stages. Capex will spill over 2-3 years. (Page 18) - Site acquisition cost: Rs. 105 crores spent on site acquisition as part of the overall capex. (Page 8) - Focused on building new biotech capabilities rather than maintenance capex. (Page 17)

- Domestic Branded Formulations (DBF) revenue targeted at Rs. 2,600 crores with 12-14% organic growth in FY25. - Consolidated revenue expected to exceed Rs. 3,000 crores with an EBITDA margin of 35%. - Biocon business forecasted to grow 27% in revenue with a margin expansion of approximately 1,000 bps. - Swiss Parenterals aims for Rs. 330 crores revenue with 14% top-line growth and 30% EBITDA growth. - Insulin franchise (including Basalog, Insugen, Xsulin, Xglar) anticipated to reach Rs. 340-350 crores, a 40% growth on the acquired base. - Strong growth expected from super-specialty segments (Critical Care, Oncology, Nephrology) at 10%+ volume growth annually. - New product launches in Cardiology (Dapagliflozin plus Metoprolol and Dapagliflozin plus Bisoprolol) planned for Q2 to aid growth. - Margin expansion driven by productivity gains, gross margin improvement, and fixed cost synergies.

- **Base Business**: Expected organic revenue growth of 12-14% with an EBITDA margin of 37% in FY25. Margin expansion driven by productivity gains, gross margin improvement, and fixed cost synergies. - **Biocon Business**: Revenue growth of 27% with an EBITDA margin improvement of approximately 1000 basis points. Biocon-2 segment expected to achieve 28% EBITDA margin, a 900 bps improvement over acquisition base, with potential for mid to late-30s margins over 2-3 years. - **Swiss Parenterals**: Projected revenue of Rs. 330 crores with a 35% EBITDA margin for the year. - **Consolidated Outlook**: FY25 revenue expected at Rs. 3,000+ crores with an EBITDA margin of 35%; consolidated margins may reach late 30s in future as manufacturing efficiency improves. - **EPS/Profitability**: Q1 showed 10% growth in cash EPS; overall profitability to improve with margin expansions and operational efficiencies.

- Swiss Parenterals has an order book of nearly Rs. 130 crores for delivery in the current year. - This is highlighted on Page 6, where the company mentions continuing to expand the product pipeline alongside this order book. - No specific details are provided about order books or pending orders for other segments or the overall company beyond this figure.